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Translocations between the human Mixed Lineage Leukemia (MLL) and AF4 Family (AFF) member genes, are 
implicated in leukemia. Mutations to AFFs can disrupt lymphopoesis, CNS development and spermatogenesis. 
However, despite the growing list of pathologies linked to AFF members, their evolutionary relationship and 
the structure/function of individual members, remain to be elucidated. Here, we first report that database min-
ing and phylogenetic analysis with AFF proteins from multiple species, revealed two monophyletic sister clades, 
suggesting a common Bilateria ancestor. We then examined the structure/function of the most recently discov-
ered AFF member, MCEF (also known as AF5q31 or AFF4). In silico, the human MCEF gene was found to have 
21 exons, and code for a protein with seven nuclear localization sequences (NLS). In HeLa cells, an MCEF-EGFP 
fusion protein, localized exclusively to the nucleus. Consequently, we made twenty constructs, expressing 
MCEF deletion mutants fused to EGFP and/or DsRed fluorescent proteins. Three distinct protein sequences, 
encoded by three separate MCEF exons, were found to mediate nuclear localization, only two of which were 
predicted in silico. Importantly, we also found that ectopic expression of MCEF, repressed HIV-1 LTR-directed 
RNA Polymerase II transcription, at the level of Tat-transactivation. We suggest that portions of MCEF could be 
exploited for chimeric transcription factor repression (CTFR) of HIV-1. 
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1.  Introduction 
Polycomb/trithorax proteins are epigenetic 
regulators of transcription [1]. The mixed lineage leu-
kemia (MLL) protein is a mammalian homologue of 
Drosophila trithorax, functioning as a transcriptional 
maintenance factor during morphogenesis [2]. In fact, 
MLL normally regulates transcription initiation and 
elongation of a specific set of HOX genes. The human 
M L L  g e n e  o n  c h r o m o s o m e  1 1  i s  f r e q u e n t l y  t r a n s l o -
cated in acute lymphoblastic leukemia (ALL), gener-
ating chimeric proteins composed of amino-terminal 
MLL and carboxyl-terminal partners [3]. The recipro-
cal chimera can also occur [4]. There is evidence im-
plicating these chimeras in dys-regulation of normal 
MLL-mediated HOX gene expression, leading to ALL 
[5]. Importantly, three AFF members (AF4, LAF4, 
MCEF, see below), are partners for MLL translocations, 
suggesting a role as transcription factors [6-12]. 
  The human AF4 gene (designated HUMAN 
AFF1 by the Human Genome Nomenclature Commit-
tee (HGNC) [13]), on chromosome 4, activates tran-
scription when fused to the DNA binding domain of 
yeast Gal 4 (GAL4), and tethered to a promoter with 
Gal 4 DNA binding sites (G4DBS) [14, 15]. In mice, 
AF4 is expressed in lymphoid tissues and brain [15]. 
Although knockout AF4 mice appear affected only in 
lymphoid tissues, it has recently been established that 
AF4 plays a role in the CNS, where a single aa muta-
tion, modifying a Siah site, is associated with Purkinje 
cell loss; highlighting that even for the best studied 
AFF member, we still know little about its normal 
function in vivo [16]. 
  The human FMR2 gene (designated HUMAN 
AFF2 by HGNC [13]) on chromosome X, has not been 
implicated in leukemia. Silencing FMR2 is involved in 
mild mental retardation (MMR) [17]. FMR2 is highly 
expressed in brain [17]. As for AF4, GAL4-FMR2 acti-
vates transcription [17].   
  The human LAF4 gene (designated HUMAN 
AFF3 by HGNC [13]) on chromosome 2, parallels AF4 
expression, and is implicated in ALL and breast cancer 
[18]. Mouse LAF4 likely acts in lymphoid and CNS 
development [19]. As for AF4 and FMR2, GAL4-LAF4, 
activates transcription [17]. 
  The human MCEF gene (designated HUMAN 
AFF4 by the HGNC [13] and also known as AF5q31) 
on chromosome 5, codes for a 1,163 aa protein with 
regions of homology to other AFF members, desig-
nated NHD, ALF, pSer, CHD [3, 9, 10, 12]. MCEF is 
expressed in adult heart, with lower levels in placenta, 
skeletal muscle, pancreas and brain [9, 10]. Higher Int. J. Biol. Sci. 2007, 3   
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expression occurs in fetal compared to adult lung and 
brain [9]. Unexpectedly, MCEF knockout mice were 
recently shown to be azoospermic [20]. 
 Despite the growing list of pathologies implicat-
ing AFF members, little is known about their struc-
ture/function relationships. For this paper, we first 
mined databases for AFF sequences from multiple 
species, and determined phylogenetically that AFFs 
form sister clades, suggesting they have a common 
Bilateria ancestor. We then characterized MCEF in 
silico, finding seven putative NLS, within 3 of 21 exons. 
I n  H e L a  c e l l s ,  w e  s h o w e d  t h a t  a  f u l l - l e n g t h  
MCEF-EGFP fusion protein was nuclear. We conse-
quently made twenty constructs expressing MCEF 
deletions, to test for functional NLS. We found that 
distinct protein sequences, encoded by three separate 
exons could mediate nuclear localization, only two of 
which were predicted in silico. Importantly, we also 
found that MCEF can directly repress RNA Poly-
merase II transcription of HIV-1 LTR-directed 
Tat-transactivation, in HeLa cells. These results estab-
lish that MCEF is a bonafide nuclear transcription 
factor, and suggest that portions of MCEF may be 
useful in designing a protein to be used in chimeric 
transcription factor repression (CTFR) of HIV-1. 
2.  Materials and Methods 
MCEF bioinformatics. The MCEF cDNA was 
re-sequenced with 3 fold redundancy, on a 310 Ge-
netic Analyzer (ABI) (GenBank accession no. 
AF213987.2) [10]. The MCEF sequence represents the 
cDNA clone used in this paper, and generates the 
MCEF protein sequence (GenBank accession no. 
AAM00184.2). The AF5q31 sequence is a distinct 
cDNA, cloned by another group, that generates a pro-
tein sequence nearly identical to MCEF (GenBank ac-
cession no. AAF18981.1) [9]. The AFF4 consensus se-
quence is a distinct hypothetical reference sequence, 
also nearly identical to MCEF (GenBank accession no. 
NP_055238). Individual AFF1 (GenBank accession nos. 
P51825, 114594998, XP_001095779.1, AAU93698.1, 
XP_223161.4), AFF2 (nos. NP_002016.2, NP_001009042. 
1, BAE02338.1, NP_032058.1, XP_001054673.1), AFF3 
(nos. AAH36895.1, XP_525831.1, XP_001104149.1, 
AAH52061.1, XP_343560.2), and AFF4 (nos. 
AAM00184.2, AAF18981.1, NP_055238, XP_517928.1, 
BAE00514.1, BAC35763.1, XP_220420.2), sequences 
were used for alignments. The out-group was Lillipu-
tian (no. NP_722863.1) [21]. ClustalW (v1.4) in 
MacVector 2.22 (Accelerys), generated alignments. 
Best tree was derived by Neighbor Joining, and node 
values obtained from 32,000 bootstraps. BLAST (NCBI) 
searches identified the longest AFF4 mRNA (no: 
NM_014423.3), used to identify intron/exon junctions 
using the chromosome 5 contig (no: NT_034772.5) [22]. 
Junctions were predicted by Spidey (NCBI) [23]. The 
NHD, ALF, pSer, CHD, and a putative MCEF Trans-
activation domain (TAD), were derived from previous 
publications, then BLAST (NCBI) was used to locate 
homologous MCEF sequences [3, 24]. The 7 PEST sites 
and 7 NLS, were predicted by PESTFIND and PSOR-
TII [16, 25].   
Molecular constructs. The -pcMCEF construct 
expresses full-length MCEF from a CMV promoter 
and +pcMCEF contains an antisense MCEF sequence 
[10]. The antisense construct was used as a control, 
instead of empty vector, since it is of the exact same 
size as the MCEF-expressing construct. The MCEF 
ORF was amplified using forward primers with XhoI, 
and reverse primers with BamHI, sites incorporated 
for cloning into pEGFP-N1 or pDsRed (Clontech). 
Primers used to generate constructs in Fig. 3 were: c - 
MN-F2 (5’-CCGCTCGAGCGGATGAACCGTGAAGA 
CCGG-3’) and MN-R2 (5’-CGCGGATCCCTAGATAT 
CAACTTGGCATCCTG-3’); d - MN-F2 and MN-R3 
(5’-CGCGGATCCTGTCTGCTGGAGGGCATGC-3’); e 
- MN-F13a (5’-CCGCTCGAGATGAGTGGATCTGAA 
AGCAGCTCTGG-3’) and MN-R7a (5’-CGCTGGATCC 
TCGGGAGATGCCTGGGATGG-3’); f - MN-F7 
(5’-CCGCTCGAGATGCCTCGTGGAGGCCTGAAGA
TAG-3’) and MN-R2; g - MN-F7 and MN-R2; h - 
MN-F20 (5’-CCGCTCGAGGCCACCATGAATATAA 
AGAAGGAGTCTAAG-3’) and MN-R20 (5’-CGCTG 
GATCCGAAGATTTACTTGTTGACTTATATTTC-3’); 
i - MN-F21 (5’-CCGCTCGAGGCCACCATGCCTCGA 
CCTACAGCAGAG-3’) and MN-R20; j - MN-F5 
(5’-CCGCTCGAGATGGAAGAGAAGGAACTTC-3’) 
and MN-R2; k - MN-F5 and MN-R2; l - MN-F12 
(5’-CCGCTCGAGATGAGGGAAATCATAGAAACA
G-3’) and MN-R11 (5’-CGCTGGATCCCCACTGCTTG 
ACTTTAAGGA-3’); m - MN-F12 and MN-R6a 
(5’-CGCTGGATCCTCACTTTCATCTGAATCTGA-3’); 
n - MN-F16 (5’-CCGCTCGAGGCCACCATGGTTTCC 
AACAAAGGCAAGAGG-3’) and MN-R9 (5’-CGCTG 
GATCCTTATGCTTCCTCTTGCC-3’); o - MN-F9 
(5’-CCGCTCGAGATGTACAAAGAAACAGAGCCG
CCC-3’) and MN-R9; p - MN-F5 and MN-R9; q - 
MN-F12 and MN-R9; r - MN-F14 (5’-CCGCTCGAGAT 
GAAGATTGACCTGAATCTT-3’) and MN-R9; s - 
MN-F16 and MN-R10 (5’-CGCTGGATCCTTGTCCTC 
CGTTTTGGG-3’); t - MN-F15 (5’-CCGCTCGAGATGA 
GTGCTGCAAAAGAAAAGG-3’) and MN-R2; u - 
MN-F11 (5’-CCGCTCGAGATGAACAGCAACAAGG 
AGACGAGTGG-3’) and MN-R2; v - MN-F22 
(5’-CCGCTCGAGGCCACCATGCCAACTCTTGATTC
TTCTAAG-3’) and MN-R22 (5’-CGCTGGATCCGCTG 
AATAATTTCTGTCATCAAAG-3’); w - MN-F15 and 
MN-R11. PCR, cloning and sequencing of constructs 
was by standard techniques. Constructs were tested 
using the T7 TNT-Coupled reticulocyte lysate system 
(Promega), per manufacturer’s recommendations, us-
ing Redivue L-[35S] methionine (GE Healthcare). 
Tissue culture and transfection. HeLa S3 cells 
(ATCC) were maintained in F-12K media, with 10% 
fetal bovine serum and 10% penicillin-streptomycin 
(Multicell), at 37°C and 5% CO2. HeLa S3 cells were 
transfected using DreamFect (Oz Biosciences), with 1.0 
μg of each construct, in 80% confluent 6-well plates. 
After 24 h, cells were observed under a confocal laser 
microscope or harvested for luciferase assays. 
Fluorescent Microscopy. Cells were routinely 
examined under an AE31 microscope (Motic). For Int. J. Biol. Sci. 2007, 3   
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confocal laser microscopy, cells were grown on No. 1 
glass cover slips (VWR International), inside 6-well 
plates, and transfected with DNA of interest. For ob-
servations under the LSM 510 microscope (Zeiss), 
cover slips were removed and cells covered with 
complete F-12K medium, containing 20 mM HEPES, 
to buffer against pH changes. The Plan-Neofluoar oil 
DIC 40x objective was used. Expression was scored as 
+ or – , in the nucleus and cytoplasm. 
Single cell expression levels. Individual cells 
were analysed with LSM 510 Image Analysis Software 
(Zeiss). Histogram data were derived from individu-
ally outlined cells and nuclei. Total Expression Level 
(TEL) for each cell, was calculated as the [(Σ (1−250) 
pixel intensities in outlined cell) x (# of pixels at each 
intensity)]. Nuclear Expression Level (NEL) for each 
cell, was calculated as ([Σ (1−250) pixel intensities in 
outlined nucleus) x (# of pixels at each intensity)]. 
Cytoplasmic Expression Level (CEL) for each cell, was 
calculated as [TEL – NEL]. Data was normalized to 
EGFP (Fig. 3, 4, 5: a) settings of laser intensity and 
pinhole aperture (5% and 135 μm), but are presented 
separately in graphs B and C, since the intensity was 
approximately 10 fold less for DsRed constructs (543 
nm) than for EGFP constructs (488 nm). The value of 
percentage change in localization (% Δ Nuclear Local-
ization), was calculated as the [(% NEL for each con-
struct) – (% NEL for EGFP alone)]. The % Δ Cytoplas-
mic Localization, was calculated as the [(% CEL for 
each construct) – (% CEL for EGFP alone)]. 
Luciferase assays. The HIV-1 subtype B LTR, 
clone pMCE36.1, was previously described and sub-
cloned into a luciferase reporter construct by standard 
techniques [26]. The HIV-1 Tat expression construct 
(pCMV-Tat), –pcMCEF and +pcMCEF constructs, 
have been previously described [10, 26, 27]. Luciferase 
assays were performed as recommended by the 
manufacturer (Promega) and activity quantitated us-
ing a 20/20 Luminometer (Turner). Triplicate results, 
were adjusted for protein content via the Bradford 
assay (Bio-Rad) and for transfection efficiencies using 
a Renilla luciferase control (Promega). The CMV-RL 
construct (Promega) was used to analyze the effects of 
MCEF on the CMV promoter, with results represented 
as fold repression, compared to fold repression of LTR, 
both in the presence or absence of Tat. A fold activity 
of 1, was considered zero fold repression (see figure 
6).  
3.  Results  
AFFs form sister clades. Few AFF sequences 
have been published. As a result, we mined databases 
to determine which species have AFF sequences. We 
found complete or partial AFF sequences in Fly, Zebra 
fish, Puffer fish, Frog, Chicken, Cow, Rat, Mouse, 
Orangutan, Macac, Chimpanzee and Humans (Fig. 1 
and not shown). To establish which AFF members 
most resemble MCEF, we phylogenetically analyzed 
AFF members from various species, and found that 
AFF1 and AFF4 are sister clades, as are AFF2 and 
AFF3, with bootstrap values of 100% and 99% (Fig. 1). 
The distinct sequences for MCEF and Af5q31, result 
from the fact that they represent nearly identical but 
distinct clones. The AFF4 sequence is also distinct, but 
nearly identical to MCEF, since it is a theoretical con-
sensus sequence. 
 
Fig. 1. AFF members form two sister clades. The tree, 
derived through phylogenetic analysis using ClustalW and 
Neighbor Joining, was created as described in Materials and 
Methods. Bootstrap values from 32,000 re-samplings, are 
given in percentage at the nodes. The outgroup sequence was 
from Drosophila melanogaster (Fly Lilliputian). Human 
MCEF is boxed in a rectangle. 
 
MCEF has seven putative NLS. In silico, the 21 
exon MCEF gene on chromosome 5 was found to span 
88,283 bp, to be transcribed into a 9,580 b mRNA and 
to code for a 1,163 aa protein, with seven putative NLS, 
distributed over 4 regions, designated 1/2, 3/4, 5, 6/7 
(Fig. 2 and Table 1). The putative NLS are outside the 
NHD, ALF, pSer, CHD and a putative transcription 
activation domain (TAD) regions [3, 24]. In silico, we 
also found seven high scoring putative PEST (PP1 to 
PP7) sequences, in addition to a previously reported 
Siah site (Fig. 2) [16, 25]. PEST and Siah1 sites are in-
volved in proteosome protein turnover [16, 25].   Int. J. Biol. Sci. 2007, 3   
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Fig. 2. MCEF gene, mRNA and protein overview. Schematic representation of the MCEF protein in relation to the AFF4 
mRNA, the 21-exon gene, and the corresponding chromosomal locus. The long (q) and short (p) arms of chromosome 5 are 
labeled and the AFF4 gene location is indicated as 5q31. The 88,283 bp AFF4 gene is represented with Exons and Introns 
positioned on a 41,199,371 bp human chromosome 5 genomic contig. The positions of 34,714,367 and 34,626,084 correspond 
to the first 5' base of AFF4 mRNA and the last 3' position at 9,580 b on the contig, respectively. The 9,580 b reference AFF4 
mRNA sequence was used to determine intron/exon boundaries (see table 1) and for the relative position of exons 1-21. The 
ATG start codon in Exon 2 and the TGA stop codon in Exon 21 are indicated. The relative positions of the MCEF open 
reading frame (ORF), poly-adenylation bases (AAA), and cap (l), are indicated. The bottom of the figure is a representation of 
the MCEF protein derived from the 1,163 aa full length ORF translation of the MCEF cDNA. NHD, ALF, pSer CHD and the 
putative TAD, are indicated as open boxes (see text) in their relative positions. Five regions (1/2, 3/4, 5, 6/7) are designated 
containing the seven NLS. See materials and methods section for further details including Genbank Accession numbers for 
sequences used. 
 
MCEF localizes to the nucleus. Although T-cells 
are a preferred target for HIV-1, the HeLa cell was 
selected for our studies because: (i) our MCEF clone 
was derived from HeLa cells, and (ii) we have previ-
ously shown that MCEF represses HIV-1 transcription 
in HeLa cells [10]. To determine MCEF localization, 
we transfected HeLa cells with a construct 
over-expressing a full-length MCEF-EGFP fusion pro-
tein. In contrast to EGFP or DsRed alone, green fluo-
rescence was strictly nuclear (Fig. 3 and 4; a and b, 
versus c). Despite the compartmentalized restriction, 
we estimated the expression at 1/20 that of EGFP (Fig. 
4, c-1 versus a, and Fig 5B upper graph). The cells in 
panel c-2 (Fig. 4) and all subsequent panels (Fig. 4, d to 
w), were photographed after laser power was adjusted 
to approximately match EGFP or DsRed expression 
(Fig. 4a and b). However, the data in Figure 5B and C 
upper graphs, is quantitative. Using this data, we cal-
culated the % change in nuclear or cytoplasmic local-
ization of EGFP, as a result of MCEF fusion, using a 
20% change as indicative of localization signals. 
Clearly, there is at least one NLS in MCEF, since its 
fusion to EGFP results in an approximately 60% 
change in nuclear localization, accompanied by a cor-
responding -60% cytoplasmic localization (Fig. 5B 
lower graph).   Int. J. Biol. Sci. 2007, 3   
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Table 1. Exon-intron structure of AFF4 gene. 
 
 
 
 
The C-terminal half of MCEF mediates nuclear 
localization. To map nuclear localization sequences in 
HeLa cells,  we transfected constructs expressing 
MCEF deletion mutants, fused to EGFP and/or DsRed 
proteins (Fig. 3, 4 and 5). N-terminal MCEF localized 
to both the cytoplasm and the nucleus, whereas 
C-terminal MCEF localized only to the nucleus (Fig. 3, 
4 and 5; d, versus f and g). This is consistent with in 
silico C-terminal prediction of NLS (see above). Fusion 
of PP3 alone to EGFP, had no effect on localization 
(Fig. 3, 4 and 5; e versus a).   
 
NLS 1, and 5, within exons XI and XII, mediate 
nuclear localization. From the C-terminal portion of 
MCEF, a construct containing NLS 1 and 2, fused to 
EGFP, resulted in nuclear localization, whereas a con-
struct with only NLS 2, did not (Fig. 3, 4 and 5; h ver-
sus i). This indicates NLS 1 is functional. However, 
constructs containing NLS 3, 4, 5, 6 and 7, also local-
ized to the nucleus (Fig. 3, 4 and 5; j, k). A construct 
with only NLS 3, 4 and 5, also localized to the nucleus 
(Fig. 3, 4 and 5; l). We also tested PP6 fused to EGFP, 
but found no effect on EGFP localization (Fig. 3, 4 and 
5; m versus a). Five additional constructs containing 
either NLS 3, 4, or sequences between NLS 3, 4 and 
NLS 1, 2, all failed to localize fused EGFP to the nu-
cleus (Fig. 3, 4 and 5; n, o, p, q, r). In contrast, a con-
struct containing NLS 3, 4 and 5, localized exclusively 
to the nucleus (Fig. 3, 4 and 5; s). This indicates that in 
addition to NLS 1, in exon XI, NLS 5 in exon XII, is 
functional.  
 
A non-NLS sequence within exon XIII, medi-
ates nuclear localization. To test NLS 6 and 7, we 
made a construct encompassing the C-terminal 
804-1,163 aa and found that it localized to the nucleus 
(Fig. 3, 4 and 5; t). Surprisingly, a further deletion to aa 
846, ablated nuclear localization, despite leaving NLS 
6 and 7 intact (Fig. 3, 4 and 5; u). We further tested 
NLS 6 and 7 directly and confirmed no nuclear local-
ization (Fig. 3, 4 and 5; v). This suggests NLS 6 and 7 
are not functional, but another sequence, containing aa 
804-845, can mediate nuclear localization. In fact, se-
quences from 804-845, were able to mediate nuclear 
localization (Fig. 3, 4 and 5; w). These results establish 
that a non-NLS sequence, within exon XIII mediates 
nuclear localization, in addition to the sequences in 
exons XI and XII, summarized in Fig. 6. Int. J. Biol. Sci. 2007, 3   
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Fig. 3. MCEF-EGFP and MCEF-DsRed constructs and localization. Schematic representation of the MCEF-EGFP and 
MCEF-DsRed constructs transfected into HeLa cells. The constructs are labelled a to w. The upper part of the diagram has the 
exons I to XXI indicated, with the aa numbers above. Beneath the upper representation are the seven putative pest domains 
(PP1 to PP7), the Siah1 site, and the seven putative NLS sequences (1/2, 3/4, 5, 6/7). Below this, the conserved NHD, pSer, 
ALF, CHD regions are indicated, for reference below and with Fig. 1. The representation of the constructs includes the 
C-terminal EGFP (black rectangles) from aa 1 to 240, and the C-terminal DsRed (white rectangles) from aa 1 to 229. The 
MCEF aa numbers fused to the respective fluorescent protein, for each construct, are indicated beside the letter designation, in 
brackets. The MCEF deletions are represented with dashed lines, to simplify comparison. Vertical lines represent the exon 
boundaries. To the right, the expression in the nucleus (N) and the cytoplasm (C) are indicated, as either negative (-), or 
positive (+). Construct letters correspond to the respective panels in Fig. 4. 
 
MCEF represses HIV-1 Tat Transactivation. Be-
cause MCEF was isolated as a co-immunoprecipitating 
p r o t e i n  w i t h  P - T E F b  ( s e e  d i s c u s s i o n ) ,  w e  d i r e c t l y  
tested its ability to impinge Tat-transactivation [10]. In 
order to ensure that our construct was in fact express-
ing MCEF, we tested the expression, in a coupled 
transcription-translation reaction, and a band of the 
expected size was detected (Fig. 7D, lane 4) [10]. In the 
absence of Tat, MCEF had a minimal effect upon 
HIV-1 LTR-directed transcription, 0.7 fold (Fig. 7A 
and 7C). However, in the presence of Tat, it repressed 
Tat-transactivation, 2.4 fold (Fig. 7B). In order to test 
for promoter specificity of the repression, we tested 
the CMV promoter in the presence or absence of Tat 
and in the presence or absence of MCEF. These were 
the exact same conditions used for the LTR experi-
ments. Under these conditions, MCEF had a minimal 
activation effect, independent of the presence or ab-
sence of Tat (Fig. 7C). Similarly, we found that the TK 
promoter was also un-affected by MCEF expression 
(not shown). Int. J. Biol. Sci. 2007, 3   
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Fig. 4. Localization of MCEF-EGFP and MCEF-DsRed proteins. Confocal laser microscopy of HeLa cells transfected 
with EGFP-expressing (a), DsRed-expressing (b), full-length MCEF-EGFP-expressing (c) and deletion mutants of 
MCEF-EGFP (e, f, h, i, j, l to w) or deletion mutants of MCEF-DsRed (d, g, k). The constructs correspond with the schematic 
representations in Fig. 3. Panels are in sets of two. The first, identified with the letter corresponding to the construct trans-
fected, was taken under fluorescent microscopy. The second, to the right, is an overlay of fluorescence and visible light mi-
croscopy images. Int. J. Biol. Sci. 2007, 3   
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Fig. 5. Single cell expression levels of MCEF-EGFP and MCEF-DsRed, fusion proteins. Individual single cells were 
analyzed with Image Analysis Software (Zeiss) and intensities derived from outlined cells. Total Expression Levels (TEL), 
Nuclear Expression Levels (NEL) and Cytoplasmic Expression Levels (CEL) were derived as described in Materials and 
Methods. The letters (a to w) correspond to those in Fig. 3 and 4. (A) Examples of 3 cells, transfected with the respective 
constructs (a, c-2 and u), used for expression level analysis (the color 3-D histogram is shown in 1, and the outlined cell and 
nucleus are shown in 2). (B) Bar graph of the Intensity of EGFP signal (collected at 488nm wavelength), in the nucleus (black 
bars) and the cytoplasm (white bars), for the respective MCEF-EGFP constructs (upper graph); and bar graph of the % change 
(D) in EGFP intensity (with respect to EGFP alone), in the nucleus (black bars) and the cytoplasm (white bars). A cut-off of 
20% was selected as indicative of specific localization (dashed line), with those above 20% indicated (nls). (C) As for B, but 
for DsRed constructs (collected at 543 nm wavelength). 
 
4.  Discussion 
All AFF sequences we mined, came from Deu-
terostomia, except the Fly sequence (Arthropoda). This 
suggests the ancestor to Deuterostome AFFs, is at least 
as old as the common ancestor to Deuterostome and 
Ecdysozoa (from which Arthropoda developed), which 
is Bilateria [28]. As more AFF-like sequences are dis-
covered in species distant to humans, they should be 
classified according to where they fall on a robust tree, 
with nodes supported by high bootstrap values. In Fly, 
there appears to be only one distantly related family 
member, Drosophila lilliputian [21]. Since three of the 
four AFFs are known to be involved in translocations, 
it is entirely possible that the four AFFs developed 
from ancestral duplications of a single sequence, as the 
Bilateria evolved, approximately 600 million years ago 
[28]. 
 Precedent for differentially spliced AFF isoforms, Int. J. Biol. Sci. 2007, 3   
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was set by OX19, an FMR2 variant [17]. PEST se-
quences are involved in proteosome pathway degra-
dation of proteins, and interestingly, a Siah1 site, con-
served in AFF members, is involved in proteosome 
pathway degradation of AFF1[16, 25]. Therefore, our 
in silico results initially suggested MCEF, or differen-
tially spliced MCEF isoforms, containing exons XI, 
and/or XII and/or XIV, would be nuclear, with ex-
pression levels of at least some isoforms, regulated by 
proteosomal turnover. The experimental data how-
ever, indicated that only the bipartite NLS 1, and NLS 
5, in exons XI and XII were functional in HeLa cells 
[29]. Interestingly, we also discovered that a non-NLS 
containing sequence, in exon XIII, mediates nuclear 
localization. One possibility is that this sequence is a 
binding region involved in co-transport via associa-
tion with another nuclear localized factor. In this re-
gards, MCEF is known to interact with such a factor, 
P-TEFb [10]. Further experiments will be required to 
test if this same interaction is involved in the nuclear 
localization through exon XIII.   
 Our results suggest that the fusion of full-length 
MCEF to EGFP, reduces expression levels by a factor 
of 20 (Fig. 5B, upper graph; a versus c-1 or c-2). How-
ever, we could not map this reduced expression level 
to specific Pest sites. Further experiments will be re-
quired to determine if the Pest sites are indeed func-
tional or not, in mediating expression levels. Alterna-
tively, Kozak sequences affect expression levels in eu-
karyotes [30]. In fact, the naturally-occurring MCEF 
Kozak sequence is weak [9, 10]. However, the weak 
Kozak sequence in our original MCEF cDNA clone, 
was replaced in the MCEF-EGFP fusion constructs. At 
any rate, our results show that MCEF isoforms with 
exons XI, XII and XIII, will be nuclear, and suggest 
translational or post-translational control of MCEF 
expression levels may be occurring. 
  MCEF was initially cloned as a protein im-
munoprecipitating with P-TEFb, itself composed of 
CDK9 and Cyclin T [10]. Importantly, HIV-1 Tat, 
P-TEFb and a nascent RNA stem-loop structure called 
TAR, form a ternary complex, permitting CDK9 to 
hyperphosphorylate the RNA Polymerase II Carboxy 
Terminal Domain (Pol II CTD) [10]. This hyperphos-
phorylation is essential for transcription elongation to 
occur at the HIV-1 LTR promoter (Fig. 7 E). Previous 
tethering of GAL4-AF5q31 or GAL4-MCEF, did not 
activate a minimal promoter with G4DBS [10, 17]. 
However, tethering of GAL4-MCEF repressed an en-
hancer containing promoter, and ectopic MCEF ex-
pression has been previously shown to repress HIV-1 
replication [10]. It is therefore significant that MCEF 
represses Tat-transactivation (this paper), and we pro-
pose the model illustrated in Fig. 7 E. In this model, 
MCEF interactions with P-TEFb would interfere with 
the proper formation of the ternary complex (see 
above), possibly inhibiting CDK9 hyperphosphoryla-
tion of the RNA Pol II CTD. This mechanism may ap-
pear to be at odds with another groups data, where 
they failed to inhibit P-TEFb phosphorylation of the 
RNA Pol II CTD, with AF5q31 [20]. However, their 
results were derived outside the cellular environment, 
and they did not look at the assembled RNA Pol II 
complex on a promoter, in the presence of Tat and 
TAR, as would be the case in our assays inside HeLa 
cells. Further experiments will be required to test our 
model, and to determine if MCEF can interfere with 
other well-known treatments that activate the HIV-1 
LTR, independent of Tat, such as ionomycin/PMA. 
 
Fig. 6. MCEF exons XI, XII and XIII, can mediate nuclear localization. Schematic representation of nuclear localization 
results for MCEF sequences transfected into HeLa cells. The exons XI to XIV are indicated, with the relative position of NLS 
identified in silico, indicated by either black or white rectangles. The sequences for these regions are indicated above (2, 4, 5, 
6) or below (1, 3, 7). The non-NLS sequence, found to mediate nuclear localization, is also indicated (8). Int. J. Biol. Sci. 2007, 3   
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Fig. 7. MCEF represses HIV-1 Tat Transactivation. (A) Bar graph showing HIV-1 LTR-Luciferase activity (LUMI-
NOSITY), in the absence of HIV-1 Tat (Y axis), with the co-transfected MCEF-expressing construct, -pcMCEF (+), or in the 
presence of the MCEF antisense construct, +pcMCEF (-) (X axis). (B) Exactly as in A, with the co-tranfection of a construct 
expressing HIV-1 Tat. (C) Fold repression of CMV promoter and LTR promoters, in the presence or absence of a 
co-transfected Tat-expressing vector. Fold repression value of 1 was considered no repression. (D) In vitro transcrip-
tion-translation of pGAL4-MCEF (Lane 1), pMN-MCEF (1-1,163)-EGFP (Lane 2), +pcMCEF (Lane 3) and -pcMCEF (Lane 
4). The size of two standards is given to the left of the autoradiogram, in KD. The -pcMCEF, expresses MCEF, whereas the 
+pcMCEF clone, expresses an MCEF antisense mRNA. (E) Cartoon of proposed mechanism for MCEF repression of HIV-1 
replication and Tat Transactivation. The HIV-1 LTR is depicted with the Luciferase reporter gene fused (right side of cartoon) 
and several DNA binding sites depicted (RBEIII/ MFNLP, NFkB, SP1, TATA). RNA Pol II is depicted after promoter 
clearance and transcription of the RNA stem-loop structure TAR. The ternary complex between Tat-Tar and P-TEFb is in-
dicated. The carboxy Terminal Domain (CTD) of RNA Pol II is shown phosphorylated, with hyperphosphorylation occurring 
through P-TEFb (1). In (2) the interaction between MCEF (Black circle) and P-TEFb would inhibit and/or disrupt the ternary 
complex from hyperphosphorylating the CTD. In (3), the cartoon suggests that if tethered to the highly conserved 
RBEIII/MFNLP site, this could increase the repressive effects of MCEF. This strategy of making a chimeric transcription 
factor, between MCEF and a component of RBF2 (USF or TFIIi), we dub Chimeric Transcription Factor repression (CTFR) 
of HIV. 
 
  Chimeric transcription factors, encompassing a 
portion of a protein encoded by one gene, fused to a 
portion of another protein encoded by a second gene, 
are naturally-occurring inside cells, for example, in the 
case of MLL-AFF member translocations (see intro-
duction). These chimeric proteins appear to be able to 
change expression patterns of sets of genes. Similarly, 
fusions between GAL4 and a long list of proteins, can 
be used to artificially tether these proteins to promot-
ers with appropriate binding sites. Engineered tether-
ing of transcription repressors to the HIV-1 LTR has 
also been shown to be possible [31]. Extending this 
line of thinking, despite the extreme sequence vari-
ability of HIV-1, there is a highly conserved DNA 
binding site, proximal to its minimal promoter, 
termed RBEIII/ MFNLP, which binds the transcrip-
tion factor RBF2. We have recently shown that RBF2 
consist of USF and TFIIi [26, 27, 32, 33, and M.C.E. 
unpublished data]. Given that MCEF represses HIV-1 
replication, that it represses transcription from an en-
hancer containing promoter with GAL4 DBS, that it 
interacts with P-TEFb, and that it represses Int. J. Biol. Sci. 2007, 3   
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Tat-transactivation (this paper) - we propose that an 
RBF2-MCEF chimeric protein, may result in potent 
Chimeric Transcription Factor Repression (CTFR) of 
HIV-1 (Fig. 7E). 
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